Trulicity Manufacturer Bridge Programs: How to Get Dulaglutide Cheaper in 2026

What Is Trulicity and Why Does Its Cost Matter?

Trulicity (dulaglutide) is a once-weekly subcutaneous GLP-1 receptor agonist approved by the FDA in September 2014 for glycemic control in adults with type 2 diabetes, with a cardiovascular risk-reduction indication added in 2020 based on the REWIND trial (N=9,901) [1]. The REWIND trial showed a 12% relative risk reduction in major adverse cardiovascular events (MACE) versus placebo over a median 5.4 years of follow-up [1].

Why the List Price Is a Problem

The retail list price of Trulicity reached roughly $935 per month in 2025 for a four-pen carton. That number appears on the FDA label and Lilly's own wholesale acquisition cost disclosures [2]. Most commercially insured patients never pay list price, but patients in high-deductible health plans, Medicare Part D coverage gaps, or without insurance frequently do.

GLP-1 receptor agonists as a class have transformed type 2 diabetes management. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 RAs for patients with established cardiovascular disease, heart failure, or chronic kidney disease regardless of baseline HbA1c [3]. Cost barriers directly undermine guideline adherence.

What "Bridge Program" Means

A manufacturer bridge program is a time-limited assistance arrangement that covers drug costs while a patient waits for insurance approval, appeals a denial, or establishes eligibility for a longer-term program. Bridge programs differ from ongoing copay cards and from full patient assistance programs (PAPs). Lilly operates all three types for Trulicity.

Lilly's Copay Card for Commercially Insured Patients

For patients with commercial (private or employer-sponsored) insurance, Lilly offers a savings card that reduces out-of-pocket cost to as low as $25 per monthly fill. The program has carried various names over the years; as of early 2026, it operates through the Lilly Savings Card portal at savings.lilly.com.

Eligibility Requirements

• Must have commercial insurance (employer-sponsored, individual marketplace, or COBRA).
• Not eligible for patients whose primary coverage is a federal program: Medicare, Medicaid, TRICARE, or VA benefits.
• Valid US prescription required; no income verification for the basic copay card.
• Lilly reserves the right to limit the total annual benefit, commonly capped at $5,600 per calendar year in recent program years.

How Much You Actually Save

A commercially insured patient with a $200 copay on a specialty tier drug pays $25 out of pocket. Lilly covers the remaining $175 per fill. Over 12 fills that is a potential $2,100 in savings, well within the annual cap. Patients in high-deductible plans who have not yet met their deductible may see higher single-fill costs; in those cases the card's dollar-amount cap per fill applies rather than the flat $25 co-pay rate, so reading the current program terms is necessary before assuming the $25 figure applies to your specific situation.

The FDA's Orange Book confirms no generic dulaglutide is currently approved [4], meaning brand-name pricing pressure will persist until patent expiry or a biosimilar pathway is established.

LillyCares Foundation: Free Drug for Uninsured or Underinsured Patients

LillyCares is Eli Lilly's patient assistance program (PAP), operated as a 501(c)(3) foundation. Qualifying patients receive Trulicity at no cost, shipped directly to the prescriber's office or, in some cases, to the patient's home.

Income and Insurance Eligibility

The general threshold has historically sat at or below 400% of the federal poverty level (FPL). For a single-person household in 2025 that corresponds to approximately $60,240 per year [5]. Household income documentation (tax returns, pay stubs, or a signed attestation) is required at enrollment and at annual renewal.

Patients with insurance may still qualify if their plan does not cover Trulicity at all or if their share of cost after insurance exceeds a defined hardship threshold. Lilly reviews these on a case-by-case basis.

Enrollment Steps

1. Download the LillyCares enrollment form from lillycares.com or call 1-800-545-5979.
2. Have your prescriber complete and sign the clinical section, including diagnosis code (E11.x for type 2 diabetes) and prescribed dose.
3. Submit income documentation.
4. Allow 2 to 4 weeks for processing; Lilly may expedite in documented clinical urgency.
5. Approved patients typically receive a 90-day supply initially, then renew quarterly.

Enrollment forms and income thresholds are updated at least annually. The figures above reflect program parameters reported in early 2026, but patients should confirm current terms directly with LillyCares before relying on them.

The Bridge Program Specifically: Covering the Gap During Insurance Appeals

When a prior authorization (PA) is denied and the prescriber files an appeal, Trulicity access can lapse for 30 to 90 days or longer. Lilly's bridge supply program provides a short-term free supply during that window.

Who Qualifies for Bridge Supply

• An active PA denial or appeal must be documented.
• The prescriber must submit the bridge request on behalf of the patient.
• Bridge supply is generally limited to one to three months and does not renew indefinitely.

Prior authorization denial rates for GLP-1 RAs remain substantial. A 2023 analysis published in JAMA Internal Medicine found that specialty drug PA denials were overturned on appeal roughly 39% of the time when patients or providers pursued the appeal process [6]. That statistic underscores why having bridge access during an appeal is clinically meaningful rather than a minor administrative convenience.

Practical Documentation Checklist

• Copy of the PA denial letter with denial reason code.
• Letter of medical necessity from the prescriber, citing relevant comorbidities (HbA1c level, cardiovascular disease status, CKD stage).
• Completed Lilly bridge request form (available through the prescriber's Lilly sales representative or the Lilly Medical Information line).

Medicare Part D and the Coverage Gap Problem

Federal law prohibits manufacturer copay cards from being used when Medicare is the primary payer. This is not a Lilly-specific restriction; it applies to all manufacturer assistance programs under the federal Anti-Kickback Statute [7].

Options for Medicare Patients

Medicare Part D patients have three legitimate pathways to lower Trulicity costs:

1. Low Income Subsidy (LIS / Extra Help). The Social Security Administration administers Extra Help, which can reduce Part D drug costs to a few dollars per fill for qualifying beneficiaries with incomes at or below approximately 150% FPL [8]. Applications are filed at ssa.gov/extrahelp.

2. State Pharmaceutical Assistance Programs (SPAPs). Many states supplement Part D with their own drug assistance. The National Council on Aging maintains a BenefitsCheckUp database covering all 50 states [9].

3. LillyCares for Medicare Patients with Inadequate Coverage. A Medicare patient whose plan does not cover Trulicity at all may qualify for LillyCares, but this requires case-by-case evaluation and is not guaranteed.

Patients in Medicare should work with a State Health Insurance Assistance Program (SHIP) counselor. SHIP provides free, unbiased insurance counseling in every state and is funded by the federal government through the Administration for Community Living [10].

How Dulaglutide's Clinical Profile Supports the Case for Access

When appealing a PA denial or arguing medical necessity for a bridge supply, it helps to understand the evidence base that supports Trulicity use.

Glycemic Efficacy Data

The AWARD trial program (eight phase 3 trials) established dulaglutide's HbA1c-lowering efficacy across doses [11]. AWARD-1 (N=976) showed dulaglutide 1.5 mg reduced HbA1c by a mean of 1.51 percentage points from baseline versus 0.99 with exenatide twice daily at 26 weeks, with P<0.001 for superiority [11].

AWARD-11 evaluated the 3.0 mg and 4.5 mg doses. At 36 weeks, the 4.5 mg dose reduced HbA1c by 1.77 percentage points versus 1.38 percentage points for the 1.5 mg dose (P<0.001) [12]. Both higher doses were approved by the FDA in 2020, giving prescribers dose-escalation flexibility without switching agents.

Cardiovascular Outcome Data

The REWIND trial (N=9,901, median follow-up 5.4 years) showed that dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 12% compared with placebo (HR 0.88, 95% CI 0.79 to 0.99) [1]. Approximately 69% of the REWIND population had no prior cardiovascular event at baseline, making this the first GLP-1 CVOT to demonstrate benefit in a predominantly primary-prevention population.

The American College of Cardiology/American Heart Association 2023 guideline on cardiovascular risk reduction in diabetes specifically names GLP-1 RAs with proven CVOT data as preferred agents in patients with or at high risk for atherosclerotic cardiovascular disease [13].

Renal Protection Signal

Secondary analyses of REWIND showed a 15% relative risk reduction in a composite kidney outcome (sustained 40% decline in eGFR, end-stage kidney disease, or renal death) with dulaglutide versus placebo [14]. The ADA's 2024 Standards of Care cite this renal signal when recommending GLP-1 RAs for patients with diabetic kidney disease [3].

These data points belong in every letter of medical necessity. An insurer that sees a patient with type 2 diabetes plus established atherosclerotic cardiovascular disease has strong guideline and outcomes-trial support for approving Trulicity rather than a less expensive sulfonylurea.

Comparing Lilly's Programs Side by Side

The table below organizes Lilly's three main Trulicity assistance tracks by patient type. Eligibility criteria and benefit amounts are subject to change; confirm current terms with Lilly before enrollment.

| Program | Best for | Insurance requirement | Income cap | Benefit | |---|---|---|---|---| | Lilly Savings Card | Commercially insured | Commercial only (no federal programs) | None | Copay reduced to ~$25/fill | | Bridge Supply | Patients during PA appeal | Any (appeal in progress) | None stated | 1 to 3 months free drug | | LillyCares PAP | Uninsured or underinsured | None required | ~400% FPL | Free drug, ongoing |

HSA and FSA Eligibility for Trulicity

Trulicity is a prescription medication, which makes it automatically eligible for payment with Health Savings Account (HSA) or Flexible Spending Account (FSA) funds under IRS Publication 502 [15]. There is no special pre-authorization required from the HSA/FSA administrator to use these funds for a prescribed medication.

Practical Points on HSA/FSA Use

Using HSA funds to pay for Trulicity effectively discounts the drug by your marginal federal income tax rate. A patient in the 22% federal bracket who spends $200 out of pocket on Trulicity saves approximately $44 in taxes by routing that payment through their HSA rather than using post-tax dollars.

HSA funds can also be used to pay copays after a Lilly Savings Card is applied, if any residual patient cost remains. The IRS confirms that out-of-pocket prescription costs, including copays, qualify as medical expenses [15].

FSA accounts carry a use-it-or-lose-it deadline, typically December 31 of the plan year, with a possible $640 rollover (2024 limit). Patients refilling Trulicity in November or December should consider whether unused FSA balances can cover those fills to avoid forfeiting funds.

Step-by-Step: Enrolling in a Lilly Program in 2026

Concrete steps reduce the administrative friction that causes patients to give up on assistance programs.

Step 1: Identify Your Eligibility Tier

Answer three questions: (a) Do you have commercial insurance? If yes, start with the Lilly Savings Card. (b) Are you uninsured or underinsured with income at or below 400% FPL? Start with LillyCares. (c) Has your commercial insurance denied a prior authorization? Request a bridge supply through your prescriber.

Step 2: Gather Required Documents

For the savings card: insurance card, prescription. For LillyCares: insurance denial letter (if applicable), income documentation, completed enrollment form signed by prescriber. For bridge supply: PA denial letter, prescriber attestation, completed bridge form.

Step 3: Submit and Follow Up

Savings card enrollment is immediate online at savings.lilly.com. LillyCares processing takes 2 to 4 weeks; call 1-800-545-5979 to check status after 10 business days. Bridge requests submitted by a prescriber office are typically processed within 3 to 5 business days.

Step 4: Renewal

Savings card renews automatically at the start of each calendar year (confirm terms). LillyCares requires annual re-enrollment with updated income documentation. Bridge supply does not renew; transition to a permanent program before bridge period expires.

What to Do If All Programs Deny You

A small number of patients fall outside every program: they earn too much for LillyCares, their insurance covers Trulicity at a high tier, and they are on Medicare. Options in this situation include:

• Therapeutic substitution with prior-authorization strategy. Other GLP-1 RAs (semaglutide as Ozempic, exenatide as Byetta/Bydureon) have different formulary placement. A prescriber can document reasons for agent-specific selection [16]. Semaglutide 0.5 mg to 2 mg weekly demonstrated superior HbA1c reduction versus dulaglutide in the SUSTAIN-7 trial (N=1,201), which may support a switch if access to semaglutide is easier [17].
• Federally Qualified Health Centers (FQHCs). FQHCs participate in the 340B Drug Pricing Program, which allows them to purchase drugs at significant discounts and pass savings to patients [18]. Patients can find a nearby FQHC at findahealthcenter.hrsa.gov.
• State Medicaid expansion. As of 2026, 40 states plus DC have expanded Medicaid under the ACA. A single adult earning up to 138% FPL ($20,783/year in 2025) may qualify [5]. Medicaid formularies vary but many cover at least one GLP-1 RA.
• NeedyMeds and RxAssist databases. Both aggregate pharmaceutical assistance programs and are updated more frequently than most third-party coupon sites. Neither replaces manufacturer programs, but both surface options that patients and providers often miss [19].

Monitoring Parameters While on Trulicity

Patients who secure Trulicity through any of these access programs should understand standard monitoring expectations to communicate effectively with their prescriber and maintain continued coverage justification.

Baseline and Ongoing Labs

• HbA1c every 3 months until at goal (typically <7.0% per ADA 2024), then every 6 months [3].
• eGFR and urine albumin-to-creatinine ratio at least annually given the renal endpoint data from REWIND [14].
• Body weight at each visit; dulaglutide produces modest weight loss (mean 3.1 kg at 52 weeks in AWARD-8) [20], which may support PA renewal arguments.

Gastrointestinal Side Effects and Adherence

Nausea, vomiting, and diarrhea are the most common adverse effects, typically peaking in the first 4 to 8 weeks. The AWARD trials reported discontinuation due to GI adverse events in approximately 5 to 8% of patients on dulaglutide [11]. Starting at 0.75 mg for 4 weeks before escalating to 1.5 mg substantially reduces GI burden, per the FDA-approved prescribing information [2].

Adherence data matter for program renewal. Patients who fill consistently demonstrate ongoing clinical need, which supports continued LillyCares enrollment and PA renewals. Missing fills without documented clinical reason can prompt payer requests for step therapy with less expensive agents.